Precision BioSciences Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: DTIL · Form: DEF 14A · Filed: Apr 25, 2024 · CIK: 1357874
| Field | Detail |
|---|---|
| Company | Precision Biosciences Inc (DTIL) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Virtual Meeting, Shareholder Vote, Precision BioSciences
TL;DR
<b>Precision BioSciences, Inc. will hold its 2024 virtual annual meeting of stockholders on June 4, 2024, encouraging shareholders to vote via electronic, telephone, or mail methods.</b>
AI Summary
PRECISION BIOSCIENCES INC (DTIL) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 annual meeting of stockholders for Precision BioSciences, Inc. will be held on June 4, 2024, at 11:00 a.m. Eastern Time. The meeting will be conducted entirely virtually via live webcast. Stockholders can vote electronically via the Internet, by telephone, or by returning a signed proxy card. Voting instructions for the virtual meeting are available at www.virtualshareholdermeeting.com/DTIL2024. The company is providing proxy materials over the Internet under SEC's 'notice and access' rules to expedite delivery and reduce costs.
Why It Matters
For investors and stakeholders tracking PRECISION BIOSCIENCES INC, this filing contains several important signals. The virtual format aims to improve accessibility and reduce costs associated with traditional in-person meetings. Encouraging early and diverse voting methods (online, phone, mail) ensures broader shareholder participation in corporate governance decisions.
Risk Assessment
Risk Level: low — PRECISION BIOSCIENCES INC shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational information, indicating a low level of immediate risk.
Analyst Insight
Review the proposals to be voted on at the June 4th annual meeting to understand key governance and strategic directions for Precision BioSciences, Inc.
Key Numbers
- 2024 — Annual Meeting Year (2024 annual meeting of stockholders)
- June 4 — Meeting Date (Annual Meeting will be held on Tuesday, June 4, 2024)
- 11:00 a.m. Eastern Time — Meeting Time (beginning at 11:00 a.m., Eastern Time)
Key Players & Entities
- PRECISION BIOSCIENCES INC (company) — Registrant name
- June 4, 2024 (date) — Date of the annual meeting
- 11:00 a.m. Eastern Time (time) — Time of the annual meeting
- 302 EAST PETTIGREW STREET SUITE A-100 (address) — Company's business and mailing address
- DURHAM (location) — City of company's address
- NC (location) — State of company's address
- 27701 (postal_code) — ZIP code of company's address
- www.virtualshareholdermeeting.com/DTIL2024 (url) — Website for voting instructions
FAQ
When did PRECISION BIOSCIENCES INC file this DEF 14A?
PRECISION BIOSCIENCES INC filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by PRECISION BIOSCIENCES INC (DTIL).
Where can I read the original DEF 14A filing from PRECISION BIOSCIENCES INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PRECISION BIOSCIENCES INC.
What are the key takeaways from PRECISION BIOSCIENCES INC's DEF 14A?
PRECISION BIOSCIENCES INC filed this DEF 14A on April 25, 2024. Key takeaways: The 2024 annual meeting of stockholders for Precision BioSciences, Inc. will be held on June 4, 2024, at 11:00 a.m. Eastern Time.. The meeting will be conducted entirely virtually via live webcast.. Stockholders can vote electronically via the Internet, by telephone, or by returning a signed proxy card..
Is PRECISION BIOSCIENCES INC a risky investment based on this filing?
Based on this DEF 14A, PRECISION BIOSCIENCES INC presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational information, indicating a low level of immediate risk.
What should investors do after reading PRECISION BIOSCIENCES INC's DEF 14A?
Review the proposals to be voted on at the June 4th annual meeting to understand key governance and strategic directions for Precision BioSciences, Inc. The overall sentiment from this filing is neutral.
How does PRECISION BIOSCIENCES INC compare to its industry peers?
Precision BioSciences, Inc. operates in the biotechnology sector, focusing on gene editing technologies.
Are there regulatory concerns for PRECISION BIOSCIENCES INC?
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
Industry Context
Precision BioSciences, Inc. operates in the biotechnology sector, focusing on gene editing technologies.
Regulatory Implications
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on at the annual meeting.
- Follow the provided instructions to vote shares electronically, by phone, or by mail.
- Access the virtual meeting webcast on June 4, 2024, to participate and vote live.
Key Dates
- 2024-06-04: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and participation.
- 2024-04-25: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine proxy statement for an upcoming annual meeting. No prior filing details are provided for comparison within this document.
Filing Stats: 4,395 words · 18 min read · ~15 pages · Grade level 10.9 · Accepted 2024-04-25 16:32:25
Filing Documents
- ny20023311x1_def14a.htm (DEF 14A) — 980KB
- ny20023311x1_pc1.jpg (GRAPHIC) — 538KB
- ny20023311x1_pc2.jpg (GRAPHIC) — 468KB
- 0001140361-24-022084.txt ( ) — 2366KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 33   ​ ​   ​ ​     ​ ​ Overview ​ ​ 33   ​ ​ Summary Compensation Table ​ ​ 33   ​ ​ Narrative Disclosure to Summary Compensation Table ​ ​ 33   ​ ​ Outstanding Equity Awards at 2023 Fiscal Year-End ​ ​ 35   ​ ​ Director Compensation ​ ​ 36   ​ ​   ​ ​   STOCK OWNERSHIP ​ ​ 40   ​ ​   ​ ​     ​ ​ Security Ownership of Certain Beneficial Owners and Management ​ ​ 40   ​ ​   ​ ​   CERTAIN TRANSACTIONS WITH RELATED PERSONS ​ ​ 42   ​ ​   ​ ​     ​ ​ Policies and Procedures on Transactions with Related Persons ​ ​ 42   ​ ​ Investors’ Rights Agreement ​ ​ 42   ​ ​ Director and Officer Indemnification and Insurance ​ ​ 42   ​ ​ Employment Agreements ​ ​ 42   ​ ​ Stock Options Grants to Executive Officers and Directors ​ ​ 42 TABLE OF CONTENTS   ​ ​   ​ ​ Page   ​ ​   ​ ​   STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS ​ ​ 42   ​ ​   ​ ​   HOUSEHOLDING ​ ​ 43   ​ ​   ​ ​   2023 ANNUAL REPORT ​ ​ 43 TABLE OF CONTENTS Precision BioSciences, Inc. 302 East Pettigrew Street, Suite A-100 Durham, North Carolina 27701 PROXY STATEMENT FOR THE ANNUAL MEETING OF STO